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Background: There has been limited study on the effect of infection with different hepatitis C virus (HCV) genotypes
on the risk of hepatocellular carcinoma (HCC) in hepatitis B virus (HBV) endemic regions of Asia.
Methods: Hazard ratios of HCC development were estimated for HBV and HCV co-infected subjects among a
community-based prospective cohort. HCV genotype was determined in HCV RNA-positive samples. Incident HCC
cases were identified through linkage to the cancer registry.
Results: HCC incidence was 79 per 100,000 person-years in the study population (50 incident cases among 6,694
individuals within 63,170 person-years with an average of 9.4 years of follow-up); seroprevalence of HBsAg and
anti-HCV was 5.2% and 5.6%. Adjusted hazard ratios of HCC by HBsAg positivity and anti-HCV positivity were 13.3
(CI: 7.3-24.4) and 6.7 (CI: 3.6-12.6). HRs of HBV and HCV monoinfection, and HBV/HCV coinfection were 17.1
(CI: 8.4-34.8), 10.4 (CI: 4.9-22.1) and 115.0 (CI: 32.5-407.3). Multiplicative synergistic effect of HBV/HCV coinfection on
HCC risk was also observed (synergy index: 4.5, CI: 1.3-15.5). Infection with HCV genotype 1 (HR: 29.7, CI: 13.6-46.8)
and mixed infection with genotype 1 and 2 (HR: 68.7, CI: 16.4-288.4) significantly elevated HCC risk, much higher
than HBV infection.
Conclusions: The effect of differences in HCV genotype and the multiplicative synergistic effect of HBV/HCV
coinfection on HCC risk shown in the present study underline the need for comprehensive identification of hepatitis
infection status in order to prevent and control HCC in this HBV endemic area.
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Epidemiologic and experimental evidence has shown
that chronic infection with hepatitis B and C virus (HBV,
HCV) is a major risk factor for hepatocellular carcinoma
(HCC) [1,2]. The highest incidence rates of HCC come
from Southeast Asia including China and the Republic of* Correspondence: Shinh@wpro.who.int
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reproduction in any medium, provided the orKorea, and sub-Saharan Africa, where HCC is frequently
caused by HBV infection, and from Japan, where HCC
is predominantly caused by HCV [3]. HBV and HCV
infection increase HCC risk some 12- to 14-fold and this
risk differs according to whether the infection is an HBV
or HCV monoinfection, or an HBV/HCV coinfection,
and depends on which genotypes of the viruses are
involved, and their viral load [4-9].
In particular, distribution of HCV genotypes varies
according to geographic regions, which raises several
issues related to their transmission and treatment. There
were not so many studies on risk difference in HCV
genotypes in general population. Some studies, including. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that HCV genotype 1b plays the most important role in
HCC development [8,10,11] but most studies included
in the meta-analysis were based on patients with chronic
hepatitis or liver cirrhosis [8].
In Korea, where the incidence rate of HCC is high
(24.5 per 100,000 [12]), the prevalence of HCV (1.3% [13])
infection is lower than that of HBV (3.2% [14]). A recent
meta-analysis of Korean data showed that the pooled
relative risk (RR) (11.5 for both sexes) of HCC among
individuals positive for antibodies against HCV (anti-
HCV) was also lower than that among individuals posi-
tive for hepatitis B surface antigen (HBsAg) (24.4 in men
and 33.7 in women) [15]. HCV genotypes 1b and 2a were
reported to be the most prevalent among six known
HCV genotypes and at least 30 subtypes [13], whereas
genotype C was predominant (99%) among the HBV gen-
otypes [16-18]. An additive effect of HBV/HCV coinfec-
tion, as well as a differing risk conferred by different
HCV genotypes on HCC development, were suggested
by a few epidemiologic studies, including a recent meta-
analysis [5]. However, there are a very limited number of
studies on the impact of HCV infection on HCC develop-
ment in Korea. Indeed, all of the studies included in the
aforementioned meta-analysis were case–control studies,
the sample sizes of which were relatively small.
In this context, using a community-based prospective
cohort design, the present study investigated HCC risk in
relation to HBV infection, HCV infection and other risk
factors, and evaluated the difference in risk between
HBV or HCV monoinfection and HBV/HCV coinfection
in the Republic of Korea. HCC risk according to HCV
genotype was also investigated.
Methods
Ethics statement
The study protocol was approved by the Institutional
Review Boards of the Seoul National University Hospital
and the National Cancer Center of Korea. All study parti-
cipants signed an informed consent form before inclu-
sion into their respective cohort.
Study participants
A community-based prospective cohort study was con-
ducted in a rural area of Korea between 1993 and 2003.
Briefly, the cohort was designed to investigate the
relationship between environmental exposures, lifestyle
factors, host factors and the risk of cancer in Korea.
Members of the cohort aged 30 years or older who were
residents of Haman (county) in Kyeongsangnam-do
(province), a rural area in the Southeastern part of the
country, with the highest reported HCC incidence, were
included in the present study. After excluding 105 cohort
members with existing cancer at enrollment, 28 cohortmembers who developed incident cancer within 6 months
of enrollment (considering asymptomatic period and late
detection of cancer), and 51 with incident non-Hodgkin
lymphoma and cholangiocarcinoma (as these cancers are
also caused by HCV infection) [19], 6 694 cancer-free
members from the cohort were included in the final
analysis.
Data collection
Cohort members completed a questionnaire and pro-
vided a blood/urine sample during a health examination
at the time of enrollment into the study. Detailed data
collection was described previously [20,21].
Socio-demographics, tobacco smoking and alcohol
drinking, HBV and HCV infection status, results of liver
function test (alanine aminotransferase [ALT] and aspar-
tate aminotransferase [AST]), fasting blood sugar (FBS),
and history of acupuncture/transfusion were included in
this analysis. Alcohol consumption was categorized as
follows: no drinking (0 g/day), moderate drinking (0.1-
23.9 g/day) and heavy drinking (≥24.0 g/day) [22]. Body
mass index (BMI) was calculated from direct measures of
height and weight and categorized according to the
World Health Organization standard for Asians
as follows: underweight (<18.5 kg/m2), normal (18.5-
22.9 kg/m2), overweight (23.0-24.9 kg/m2), and obese
(≥25.0 kg/m2) [23].
HBV and HCV testing
Enzyme immunoassay (AxSYM, Abbott Laboratories,
Abbott Park, Illinois, USA) was used to determine HBV
and HCV infection. Samples were tested for seropositiv-
ity to HBsAg, antibodies against hepatitis B surface anti-
gen (anti-HBs) and anti-HCV for all study participants.
HCV RNA viremia was confirmed by nested reverse
transcript-polymerase chain reaction or by nucleic acid
testing (NAT) (COBAS AMPLICOR HCV MONITOR
test, version 2.0, Roche Molecular Systems, Branchburg,
New Jersey, USA) in anti-HCV-positive samples. HCV
genotypes were determined by the Okamoto’s method
[24] or by line-probe assay (VERSANT HCV genotype
assay (LiPA), Innogenetics, Ghent, Belgium) in HCV
RNA-positive samples.
Cancer ascertainment
On December 31, 2008, 50 HCC cases were identified in
the study population through computerized record link-
age to the Korea National Cancer Incidence Database
of the Korean Central Cancer Registry, a very reliable
registry showing 95% completeness [12].
Statistical analysis
The Cox proportional hazards model was used to esti-
mate the adjusted hazard ratios and corresponding 95%
Table 1 General characteristics of 6,694 study














Education Under middle school 1029(38.4) 2490(92.8)
Upper middle school 1634(60.9) 1493(55.7)
Unknown 19(0.7) 29(1.1)
Job Farmer 1598(59.6) 2136(79.6)
Other 1084(40.4) 1876(69.9)
Unknown 455(17.0) 717(26.7)
Smoking Non-smoker 554(20.7) 3587(133.7)
Ex-smoker 521(19.4) 66(2.5)
Current smoker 1596(59.5) 337(12.6)
Unknown 11(0.4) 22(0.8)
Alcohol drinking Non-drinker 813(30.3) 3437(128.2)
Ex-drinker 246(9.2) 66(2.5)
Current drinker 1604(59.8) 470(17.5)
Unknown 19(0.7) 39(1.5)









history No 1890(70.5) 2744(102.3)
Yes 85(3.2) 191(7.1)
Unknown 707(26.4) 1077(40.2)
HBsAg Negative 6113(227.9) 2437(90.9)
Positive 349(13) 154(5.7)
Unknown 232(8.7) 91(3.4)
Anti-HBs Negative 1151(42.9) 1652(61.6)
Positive 1422(53) 2200(82)
Unknown 109(4.1) 160(6)
Anti-HCV Negative 2456(91.6) 3627(135.2)
Positive 133(5) 242(9)
Unknown 93(3.5) 143(5.3)
Table 1 General characteristics of 6,694 study
participants in Korea, 1993-2003 (Continued)




ALT (U/L) <30U/L 1799(67.1) 3284(122.4)
≥30U/L 756(28.2) 594(22.1)
Unknown 127(4.7) 134(5)
AST (U/L) <35U/L 1794(66.9) 3338(124.5)
≥35U/L 759(28.3) 535(19.9)
Unknown 129(4.8) 139(5.2)
SD, standard deviation; BMI, body mass index; HBsAg, hepatitis B surface
antigen; anti-HBs, antibodies against hepatitis B surface antigen; anti-HCV,
antibodies against hepatitis C virus; FBS, fasting blood sugar; ALT, alanine
aminotransferase; AST, aspartate aminotransferase.
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pendent contribution of each risk factor to the develop-
ment of HCC, using SAS statistical software version 9.1
(SAS Institute, Inc., North Carolina, USA). The adjusted
population-attributable fraction and the 95% CIs of HCC
associated with HBV or HCV infection in the study
population was estimated using STATA software version
10.0 (StataCorp, Texas, USA). The synergistic effect of
HBV/HCV coinfection was computed by applying the
synergy index (SI) proposed by Rothman [25,26].Results
The demographic characteristics of the cohort are shown
in Table 1. Tobacco smoking, alcohol drinking, obesity
and history of acupuncture were very common (28.9%,
31.3%, 29.5% and 49.1%, respectively) in the study popu-
lation, whereas history of blood transfusion was relatively
rare (4.1%). The seroprevalence of HBsAg, anti-HBs and
anti-HCV was 5.2%, 56.4% and 5.6%, respectively
(Table 1).
The incidence of HCC in the study population was
79.2 per 100,000 person-years ([34 men and 16 women]
50 incident cases among 6,694 individuals within 63,170
person-years with an average of 9.4 years of follow-up).
Table 2 shows the HRs and corresponding 95% CIs of
HCC according to selected risk factors. Adjusted HRs
of developing HCC by HBsAg positivity and by anti-
HCV positivity were 13.3 (95% CI=7.3-24.4) and 6.7
(95% CI=3.6-12.6), respectively. Higher AST (≥30u/L)
and ALT (≥35u/L) levels were significantly related to
increased HCC risk. However the other potential risk
factors except heavy alcohol drinking (aHR=2.2, 95%
CI=1.1-4.4) were not significantly related to HCC risk
in the multivariate model.
Table 2 Relative risks (RRs) and 95% confidence intervals (CIs) of hepatocellular carcinoma (HCC) according to selected
characteristics
Person-years No. of HCC Crude RR (95% CI) Adjusted HRa (95% CI) Adjusted HRb (95% CI)
HBsAg
Negative 57,319 28 1.0 (reference) 1.0 (reference) 1.0 (reference)
Positive 3,115 18 12.0 (6.6-21.7) 12.5 (6.9-22.7) 13.3 (7.3-24.4)
Unknown 2,737 4 2.7 (0.9-7.8) 2.4 (0.8-7.0) 0.1 (0.01-0.5)
Anti-HCV
Negative 56,516 31 1.0 (reference) 1.0 (reference) 1.0 (reference)
Positive 3,880 15 6.9 (3.7-12.7) 7.0 (3.8-13.1) 6.7 (3.6-12.6)
Unknown 2,774 4 2.5 (0.9-7.0) 2.3 (0.8-6.5) 0.1 (0.01-0.4)
FBS (mg/dL)
<100 26,930 15 1.0 (reference) 1.0 (reference)
100-126 11,737 11 1.6 (0.7-3.5) 1.6 (0.7-3.4)
≥126 5,746 6 1.8 (0.7-4.6) 1.6 (0.6-4.1)
Unknown 18,757 18 1.7 (0.9-3.4) 1.7(0.9-3.4)
AST (U/L)
<35 48,247 11 1.0 (reference) 1.0 (reference)
≥35 11,890 36 13.5 (6.9-26.6) 11.3 (5.7-22.5)
Unknown 3,033 3 3.8 (1.0-13.8) 3.6 (0.99-13.2)
ALT (U/L)
<30 47,841 15 1.0 (reference) 1.0 (reference)
≥30 12,374 32 8.5 (4.6-15.7) 8.3 (4.4-15.6)
Unknown 2,955 3 2.8 (0.8-9.9) 2.8 (0.8-9.9)
Alcohol drinking (g/day)
0-23.9 51,193 30 1.0 (reference) 1.0 (reference)
≥24 7,214 16 3.8 (2.1-7.0) 2.2 (1.1-4.4)
Unknown 4,763 4 1.4 (0.5-4.0) 1.0 (0.3-2.8)
Tobacco smoking
Never smoker 40,375 20 1.0 (reference) 1.0 (reference)
Past smoker 4,826 7 3.1 (1.3-7.3) 1.2 (0.4-3.3)
Current smoker 17,638 23 2.7 (1.5-4.8) 1.3 (0.6-2.6)
Unknown 331 0 - -
Body mass index (kg/m2)
<18.5 2,463 2 0.8 (0.2-3.5) 0.72(0.17-3.06)
18.5-22.9 25,634 25 1.0 (reference) 1.0 (reference)
23.0-24.9 15,241 8 0.5 (0.2-1.2) 0.6 (0.3-1.4)
≥25.0 18,780 13 0.7 (0.4-1.4) 0.96 (0.5-1.9)
Unknown 1,052 2 2.1 (0.5-8.7) 2.2 (0.5-9.5)
History of acupuncture
Never 27,378 27 1.0 (reference) 1.0 (reference)
Ever 27,998 20 0.8 (0.4-1.4) 0.8 (0.5-1.5)
Unknown 7,794 3 0.4 (0.1-1.3) 0.5 (0.2-1.7)
History of transfusion
No 40,673 31 1.0 (reference) 1.0 (reference)
Yes 2,132 2 1.3 (0.3-5.4) 1.5 (0.4-6.4)
Unknown 20,365 17 0.98 (0.5-1.8) 1.1 (0.6-2.0)
HBsAg, hepatitis B surface antigen; anti-HCV, antibodies against hepatitis C virus; FBS, fasting blood sugar; ALT, alanine aminotransferase; AST, aspartate
aminotransferase. aAge- and sex-adjusted. bAge-, sex- and HBsAg/anti-HCV positivity-adjusted.
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Table 3 Hazard Ratios (HRs) and 95% confidence intervals (CIs) of hepatocellular carcinoma (HCC) according to
hepatitis B and C virus infection status
Infection status No. of subjects Person-years No. of HCC HRa (95% CI)
HBsAg(−) / anti-HCV(−) 5744 53,504 16 1.0 (reference)
HBsAg(+) / anti-HCV(−) 335 2,981 15 17.1 (8.4-34.8)
HBsAg(−) / anti-HCV(+) 360 3,731 12 10.4 (4.9-22.1)
HBsAg(+) / anti-HCV(+) 14 133 3 115.0 (32.5-407.3)
SI and 95% CI: 4.5 (1.3-15.5)b
HBsAg, hepatitis B surface antigen; anti-HCV, antibodies against hepatitis C virus. aHR: age- and sex-adjusted. bSI: synergy index=(RR11-1)/(RR01+RR10-2), in which
RR11=relative risk of the joint effect of two risk factors; RR01 and RR10=relative risk of each risk factor in the absence of the other. Two hundred and forty-one
subjects including 4 HCC cases had no information on HBsAg or anti-HCV, and were excluded from the analysis.
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of which 3 were HCC cases. Age- and sex-adjusted HRs of
HBV monoinfection, HCV monoinfection and HBV/HCV
coinfection for HCC were 17.1 (95% CI=8.4-34.8), 10.4
(95% CI=4.9-22.1) and 115.0 (95% CI=32.5-407.3), respec-
tively. The synergistic effect of HBV/HCV coinfection was
more than additive and was statistically significant (SI=4.5,
95% CI=1.3-15.5) (Table 3).
Additional file 1: Table S1 shows the distribution of
HCV genotypes among 142 HCV RNA-positive subjects
in the study population. As shown in Table 4, HCV geno-
type 1 (mostly 1b) significantly elevated HCC risk
(adjusted HR=29.7, 95% CI=13.6-46.8), whereas genotype
2 did not. HR of HCC in individuals multiply infected
with HCV genotype 1 and 2 (adjusted HR=68.7, 95%
CI=16.4-288.4) was much higher than in monotypic in-
fection with genotype 1 but the 95% CI was very wide
and overlapped. The adjusted HR for past history of
HCV infection (anti-HCV-positive but HCV RNA-nega-
tive) was 2.6 (95% CI=0.6-11.5) (Table 4).
The population-attributable fraction of HCC due to
HBV and HCV infection were 36.9% (95% CI=20.0-50.2%)
and 26.6% (95% CI=11.3-39.2%), respectively, in the study
population (data not shown).
Discussion
The present study provides a comprehensive estimation
of HCC risk according to HBV and HCV mono- and
coinfection, using data from a community-basedTable 4 Hazard ratios (HRs) and 95% confidence intervals (CI







subjects No. of HCC Person
Negative 6083 31 56,516.3
Positive Positive 1 52 8 476.5
2 84 1 850.7
1 & 2 6 2 51.1
Negative 109 2 1,045.2
aHR: age- and sex-adjusted. bHR: age-, sex- and HBsAg positivity-adjusted. Two hun
anti-HCV, and were excluded from the analysis.prospective cohort study in an area of Korea where
HCC incidence is high. HBV is by far the most import-
ant risk factor for HCC in Korea. To our knowledge,
this is the first study to explore the risk of HCV and
discover the synergistic effect of HBV/HCV coinfection
for HCC in a prospective cohort study in the general
Korean population. Furthermore, in the current study
it was evident that HCV genotype 1b increased HCC
risk significantly more than genotype 2.
The role of chronic infection with HBV in the etiology
of HCC is well established [1,2]. A community-based
prospective cohort study titled the Risk Evaluation
of Viral Load Elevation and Associated Liver Disease/
Cancer-Hepatitis B Virus (REVEAL-HBV) study in Taiwan
has reported high serum HBV DNA level, HBV genotype
C, precore G1896A mutant and basal core promoter
A1762T/G1764A double mutant as predictors of HCC
risk [9,27]. The adjusted HR (13.7) of HCC by HBsAg
positivity in the present study was compatible with previ-
ous study results, including two recent meta-analyses:
one that included 37 case–control and 10 cohort studies
conducted worldwide [5], and another that used Korean
data [15]. In addition, the risk of HCC by HBV infection
was around two-fold higher than by HCV infection in
present study.
One recent meta-analysis estimated the RR of HCC
to be as much as 12-fold higher in people infected with
HCV [5]. However, in Korea, there was no report of the
RR of HCV, although some case–control studies reporteds) of hepatocellular carcinoma (HCC) according to
-years
Incidence
(100,000 person-year) HRa (95% CI) HRb (95% CI)
54.9 1.0 (reference) 1.0 (reference)
1,678.9 28.3 (13.0-61.5) 29.7 (13.6-46.8)
117.6 2.1 (0.3-15.4) 2.2 (0.3-16.2)
3,913.9 65.0 (15.5-272.3) 68.7 (16.4-288.4)
191.4 3.4 (0.8-14.4) 2.6 (0.6-11.5)
dred and thirty-six subjects including 2 HCC cases had no information on
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a pooled odds ratio of HCC of 11.5 for anti-HCV-positive
individuals [15]. In this respect, the present study contri-
butes more evident data on the effect of HCV infection on
HCC risk in Korea to the scientific literature by reporting
RRs from a prospective cohort study, although the RR of
HCC by anti-HCV positivity was lower than expected.
The synergistic effect of HBV/HCV coinfection on
HCC risk (SI=4.5, 95% CI=1.3-15.5) identified in this study
was another meaningful finding. Indeed, HBV/HCV coin-
fection is not uncommon, particularly in countries with
a high prevalence of HBV or HCV, as the two viruses
share with some modes of transmission [5].
It was not clear if there is a risk difference between
HCV genotype 1 and 2 regarding the previous studies
in Korean, even though HCV genotype 1b and 2a are
dominant. The present study suggested that the HR of
HCC was significantly higher in individuals infected with
HCV genotype 1 (adjusted HR=29.7, 95% CI=13.6-46.8)
than genotype 2 (adjusted HR=2.2, 95% CI=0.3-16.2).
This strongly supports the results from a recent meta-
analysis, which suggested that subjects infected with
HCV genotype 1b had almost double the HCC risk of
those infected with other HCV genotypes [8]. Moreover,
the present study showed multiplicative increase in HR
of HCC in individuals who had mixed infection with
HCV genotype 1 and 2 (adjusted HR=68.7, 95% CI=16.4-
288.4), compared to HR of solitary genotype 1 or 2 infec-
tion. To the best of our knowledge, our study is the first
to show this multiplicative relationship. HCV genotype is
an important determinant of the virologic response to
HCV treatment, whereas differences in disease pathogen-
esis among genotypes may also exist. Genotype 1 is asso-
ciated with a more aggressive disease, worse response to
therapy, and higher risk of cirrhosis and HCC develop-
ment [8]. There are limited studies on HCV mixed geno-
type infection among high-risk individuals [31,32] but
pathogenecity of mixed infection and its effect on disease
progression and treatment have not yet been elucidated.
On the other hand, HBV genotype was not evaluated in
the present study as genotype C was predominant (99%)
among the HBV genotypes in Koreans [16-18]. In the RE-
VEAL study, HBV genotype C showed higher risk of
developing HCC (aRR=1.76; 95% CI=1.19-2.61) and cir-
rhosis compare to HBV genotype B [33].
There is convincing evidence that alcohol drinking
and tobacco smoking increase the risk of primary HCC
[34-36] and synergistic effects between hepatitis infection
and tobacco smoking or alcohol drinking in the develop-
ment of HCC has been recently suggested [37-41]. Heavy
alcohol drinking significantly elevated HCC risk after
adjustment in this study. Tobacco smoking elevated HCC
risk in the crude analysis, but was not significant after
adjustment. Neither FBS level or obesity were related toHCC risk in this study, although there is growing evi-
dence suggesting that obesity and diabetes mellitus (DM)
might be independent risk factors for HCC [20,39,42-45].
There was a substantial amount of missing information
on FBS (27% of the study population). However, the
HCC risk was not statistically significant (aHR=1.7, 95%
CI=0.9-3.4) in the group of unknown FBS. In addition,
the HCC risk was not elevated among subjects with DM
history, as a proxy of FBS in the independent regression
analysis (data not shown). Insignificant result of DM and
obesity in risk of HCC development may be due to pre-
dominant role of HBV and HCV as a risk factor of HCC
in this study population. Dietary ingestion of aflatoxins,
one of the risk factor of HCC in developing countries, is
very rare in Korea.
The present study offers comprehensive scientific evi-
dence on the effect of HBV and HCV infection, as well as
some other potential risk factors, on HCC development.
Nevertheless, it has several limitations that should be
considered when interpreting its data. Firstly, the size of
the case population was not very large (50 HCC cases).
In particular, a very small number of HCC cases were
identified in each category of HCV genotype, including
only 1 HCC case in the group infected with HCV geno-
type 2. Coinfection with HCV genotype 1 and 2 showed
higher HR than genotype 1 alone, but their 95% CI were
very wide and overlapping due to small number of HCC
cases. However, considering the relatively lower pre-
valence of HCV infection in Korea, and the results of
this community-based long-term prospective follow-up
study are valid enough to support a causal relationship.
Secondly, the risk factors were investigated at cohort
enrollment, with no repeated measure. Thus there were
no considerations of updated information for changes
in infection status, interventions for liver diseases and/or
health behaviors that took place after study recruitment.
Thirdly, viral load of HBV and HCV infection was not
evaluated in this study. Serum HBV DNA level is a major
predictor of HCC development [9]. Patients with a high
viral load of HCV respond poorly to interferon therapy
[46] and had a significantly higher HCC risk (RR, 2.35;
95% CI, 1.02-5.43) than did those with a low viral load
after interferon treatment [47]. However the current
study could not provide HCC risk by viral load of HBV
and HCV.
Compared to hospital-based case–control studies in
Korea (HBsAg 65.4-72.3%; anti-HCV 7.6-19.3%) [28-30],
the seroprevalence of HBsAg (39.1%) and anti-HCV
(32.6%) among HCC cases in the present study was rela-
tively low. Although the serological evidence of chronic
infection with HBV and HCV remains relatively constant
over time, there is a possibility that infection status
can change between baseline and at diagnosis of HCC.
Otherwise occult HBV or HCV infection may exist in
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HCV infection. Recently there has been growing evidence
of occult HBV and HCV infection. Occult HBV infection
was found in 0.7% of HBsAg-negative individuals in the
general adult population in Korea [48]. Although the
mechanism and clinical implications have not yet been
elucidated, occult HBV infection can also be transmitted
and may contribute to the development of HBV-
associated diseases such as HCC [49,50].
Nevertheless, this study also has much strength. It is a
prospective community-based cohort study that was able
to link to a national cancer registry to evaluate the causal
relationship of HBV, HCV and other behavioral risk fac-
tors with HCC development, while all previous cohort
studies reporting the RRs of HCC by viral hepatitis infec-
tion have used secondary data (i.e., medical insurance
claims) and included no information about HCV infec-
tion and related behavioral risk factors (e.g., blood trans-
fusion and acupuncture) [45,51,52]. In addition, the
present study provides additional evidence on HCC in
an HBV endemic area with comprehensive analyses of
HCV infection, especially for different HCV genotypes
and coinfection with HBV.
Conclusions
The present findings add to previous observations sug-
gesting that HBV infection is by far the most important
risk factors for HCC in HCC prevalent and HBV endemic
areas. Furthermore, investigation of the distribution of
different HCV genotypes, as well as the differences in
HCC risk by HCV genotype and its coinfection with
HBV, may significantly contribute to disease control, or
progresses in prevention, such as the development of an
effective vaccine, or implementation of an HCC screening
program, to improve disease outcome.
Additional file
Additional file 1: Table S1. Distribution of hepatitis C virus (HCV)
genotypes among 142 HCV RNA-positive subjects in the study
population.
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